Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 22Prostatic Neoplasms, Castration-Resistant 4Non-metastatic Castration-resistant Prostate Cancer 4Prostatic Diseases 2Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Hormone-sensitive Prostate Cancer 2Male Urogenital Diseases 2Biochemically Recurrent Prostate Cancer 2Urogenital Neoplasms 1Urogenital Diseases 1Refractory or Relapsed Solid Tumors 1Prostate Cancer Non-Metastatic 1Non-metastatic Prostate Cancer 1Neoplasms by Site 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1High-Risk Localized Prostate Cancer 1Healthy Volunteers 1Genital Diseases, Male 1Carcinoma, Non-Small-Cell Lung 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

darolutamide 2pembrolizumab 1olaparib 1gedatolisib 1enfortumab vedotin 1Radiation Dose Hypofractionation 1Pluvicto 1Mitomycin 1Gemcitabine 1Fluorouracil 1Cisplatin 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Male Urogenital Diseases × darolutamide × Clear all
NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT07103018 2026-03-23

STRIKE-001

K36 Therapeutics, Inc.

Phase 1 Recruiting
144 enrolled
Genitourinary

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡